 □ Women's & Children's Hospital □ Child & Adolescent Mental Health Service (please tick check box for appropriate site) ANTIPSYCHOTIC MONITORING CHART 					PATIENT LABEL						
					UR Number:						
					Surname:						
					Given Names:						
					D.O.B.:Sex:						
User Guide A new chart should be started when:											
Initiating Antipsychotic - start in "New Antipsychotic" sections, fill in "Baseline" and follow with recommended monitoring to the right (but omit "Ongoing Starting Point")											
Switching Antipsychotics - start in "New Antipsychotic" sections, fill in "Baseline" and follow with recommended											
monitoring to the right (but omit "Ongoing Starting Point")											
Ongoing (starting to monitor but not initiating) - start in "Ongoing Use" sections, fill in "Ongoing Starting Point" (because a real baseline can't be obtained) and then follow with recommended monitoring to the right											
Ongoing (previous chart is full) – start in "Ongoing Use" sections, omit "Ongoing Starting Point" (because baseline on a previous chart) and follow with recommended monitoring to the right											
NOTE: A detailed User Guide is available at: http://www.wch.sa.gov.au/antipsychotic											
Chart data (fill out when starting each new chart)											
Antipsychotic Name:											
Chart N° for Patient: Date Chart Started://											
Antipsychotic Use Status: [please tick one] 1. Initiating □ 2. Switching □ 3. Ongoing □											
Risk factors (check at baseline & annually) [tick if applicable]											
□ smoking □ personal/family history of diabetes □ low level of activity											
□ personal/family history of heart disease □ poor diet □ overweight or obese											
□ ethnicity (please specify)(eg Indigenous Australian, Pacific Islander, Asian, African)											
□ other medications (please sp	ecify)										
Name:						Date://					
2 Massures recommended	l for all an	tinovohoti	ioo (basali	ao monthly	for 2 mont	ha than av	ory 2 mont	ho)			
2. Weasures recommended	ded for all antipsychotics (baseline, mod New Antipsychotic Ongo				oing Ongoing Use						
Investigations	Baseline	Month 1	Month 2	Starting Point	Month 3	Month 6	Month 9	Month12			
-	Baccinic	World	WOTHER 2	Point	Wieman	Wienare	Wioritino	World112			
Date of measurement											
Daily Dosage (mg)											
Weight (kg)											
Height (m)											
Blood Pressure (sitting)											
Name, Signature & Designation											
Calculations	Baseline	Month 1	Month 2		Month 3	Month 6	Month 9	Month12			
Body Mass Index (BMI) (kg/m²)					1						
BMI-For-Age Percentile					1						
BMI Z Score (if BMI>97th percentile)					1						
Name, Signature &					1						
Designation											
		D	Original in		<u> </u>						

ReflexPrinting.com.au WCH093 Revised November 2011 Version 1.2

3. Blood test									ırly)			
Bloods should be taken in the mornii		New Antip					Ongoing		Ong	Ongoing Use		
Investigations			Baseline			Month 3		Starting Point		Month 12		
Date of blood taken								Ollit				
Total Cholesterol *												
Triglycerides *	Triglycerides *											
Blood Glucose												
White Blood Cell (WBC) Count †												
Neutrophil Cou	nt †											
Liver Function Tests (Normal Y/N) #												
Urea & Electrolytes (Normal Y/N) #												
Prolactin **	· · · · · · · · · · · · · · · · · · ·											
Name, Signature &												
Designation												
4.1 Questions to ask for all antipsychotics to monitor for extrapyramidal side effects ** (baseline, monthly for 3 months, then every 3 months) New Antipsychotic Ongoing Ongoing Use												
(Observations		Baselin		Month	Sta	rting	Month	Month	Month		
(please indica	te with a tick		Dasciiii	1	2	Po	oint	3	6	9	12	
Any muscular to ie dystonia?	Any muscular tremors or spasms ie dystonia?											
Any muscular s	Any muscular stiffness or rigidity											
ie Parkinsonism? Any restlessness or agitation ie akathisia?					\mathbf{I}							
Any involuntary hyperkinetic movements ie dyskinesia?												
4.2 Questio						nitor f	or hy	perprola	actinaem	iia **		
(baseline	e, monthly fo	r 3 months, th		•		One	o in a					
				Antipsychotic		oing rting	Ongoing Use					
Observations (please indicate with a tick = yes, x = no)		Baselin	e Month	Month 2	Po	oint	Month 3	Month 6	Month 9	Month 12		
Any milk leakage from your breasts?												
Any breast enlargement?					╁							
Have menstrual periods ceased or become irregular?					1							
Any loss of sexual function or desire?												
Stunted growth or delayed puberty?					╁							
Name, Signature &					\blacksquare							
Designation												
5. Interventi	ions require	ed										
	Baseline	Month 1	Month 2	Ongo Starting		Month 3		Month 6	Month	19 N	Month 12	
	☐ None	☐ None	☐ None			None		None	☐ Nor	ne 🗆	None	
Intervention required if abnormality detected												
Name, Signature & Designation												
Legend: * if any abnormalities are detected, a complete lipid profile is recommended † optional for patients prescribed clozapine because mandatory blood monitoring involving weekly testing for the first 18 weeks then monthly thereafter is recorded elsewhere # if No, indicate abnormality ** pay particular attention with risperidone, amisulpride, olanzapine and first generation antipsychotics ** if any abnormalities are detected, a complete lipid profile is recommended mg = milligram kg = kilogram m = metres BMI = Body Mass Index Y = Yes												